O	0	1	A
O	2	12	randomized
O	13	18	phase
O	19	21	II
O	22	27	trial
O	28	41	investigating
O	42	45	the
O	46	52	effect
O	53	55	of
O	56	64	platelet
O	65	73	function
O	74	84	inhibition
O	85	87	on
O	88	99	circulating
O	100	105	tumor
O	106	111	cells
O	112	114	in
O	115	123	patients
O	124	128	with
O	129	139	metastatic
O	140	146	breast
O	147	153	cancer
O	153	154	.

O	155	163	Blockade
O	164	166	of
O	167	175	platelet
O	176	186	activation
O	187	190	and
O	191	202	aggregation
O	203	206	can
O	207	214	inhibit
O	215	225	metastasis
O	226	228	in
O	229	240	preclinical
O	241	247	models
O	248	251	and
O	252	254	is
O	255	265	associated
O	266	270	with
O	271	277	cancer
O	278	288	prevention
O	288	289	.

O	290	292	To
O	293	297	test
O	298	305	whether
O	306	316	disruption
O	317	319	of
O	320	328	platelet
O	329	337	function
O	338	342	with
B-intervention	343	354	clopidogrel
I-intervention	355	358	and
I-intervention	359	366	aspirin
O	367	372	would
O	373	381	decrease
O	382	385	the
O	386	392	number
O	393	395	of
O	396	407	circulating
O	408	413	tumor
O	414	419	cells
O	420	421	(
O	421	425	CTCs
O	425	426	)
O	427	429	in
O	430	438	patients
O	439	443	with
O	444	454	metastatic
O	455	461	breast
O	462	468	cancer
O	468	469	,
O	470	471	a
O	472	482	randomized
O	483	488	phase
O	489	491	II
O	492	497	study
O	498	501	was
O	502	511	performed
O	511	512	.

B-eligibility	513	521	Patients
I-eligibility	522	526	with
I-eligibility	527	537	metastatic
I-eligibility	538	544	breast
I-eligibility	545	551	cancer
I-eligibility	552	555	who
I-eligibility	556	560	were
I-eligibility	561	564	not
I-eligibility	565	574	currently
I-eligibility	575	584	receiving
I-eligibility	585	594	cytotoxic
I-eligibility	595	607	chemotherapy
O	608	612	were
O	613	621	eligible
O	621	622	.

O	623	631	Patients
O	632	636	were
O	637	647	randomized
O	648	650	to
O	651	658	receive
O	659	665	either
O	666	677	clopidogrel
O	678	681	and
O	682	689	aspirin
O	690	692	or
O	693	695	to
O	696	697	a
B-control	698	705	control
I-control	706	711	group
O	712	721	receiving
O	722	724	no
O	725	734	treatment
O	734	735	.

O	736	746	Phlebotomy
O	747	750	was
O	751	760	performed
O	761	763	at
O	764	772	baseline
O	772	773	,
O	774	776	at
O	777	778	2
O	779	782	and
O	783	784	4
O	785	790	weeks
O	790	791	,
O	792	795	and
O	796	803	monthly
O	804	814	thereafter
O	815	817	to
O	818	824	obtain
O	825	834	specimens
O	835	837	to
O	838	844	assess
O	845	848	CTC
O	848	849	,
O	850	858	platelet
O	859	870	aggregation
O	870	871	,
O	872	875	and
O	876	884	thrombin
O	885	893	activity
O	893	894	.

O	895	898	The
O	899	906	primary
O	907	910	end
O	911	916	point
O	917	920	was
O	921	924	the
B-outcome-Measure	925	935	proportion
I-outcome-Measure	936	938	of
I-outcome-Measure	939	947	patients
I-outcome-Measure	948	952	with
I-outcome-Measure	953	963	detectable
I-outcome-Measure	964	968	CTCs
O	969	971	at
O	972	973	1
O	974	979	month
O	979	980	.

B-total-participants	981	986	Forty
I-total-participants	986	987	-
I-total-participants	987	992	eight
O	993	1001	patients
O	1002	1006	were
O	1007	1015	enrolled
O	1016	1019	and
B-total-participants	1020	1022	42
O	1023	1027	were
O	1028	1037	evaluable
O	1038	1040	at
O	1041	1042	1
O	1043	1048	month
O	1048	1049	.

O	1050	1058	Baseline
O	1059	1062	CTC
O	1063	1070	numbers
O	1071	1075	were
O	1076	1077	≥
O	1078	1079	5
O	1080	1082	in
O	1083	1085	13
O	1085	1086	%
O	1087	1090	and
O	1091	1092	≥
O	1093	1094	1
O	1095	1097	in
O	1098	1100	65
O	1100	1101	%
O	1102	1104	of
O	1105	1113	patients
O	1113	1114	.

O	1115	1122	Despite
O	1123	1131	adequate
O	1132	1140	platelet
O	1141	1149	function
O	1150	1160	inhibition
O	1161	1163	in
O	1164	1167	the
O	1168	1177	treatment
O	1178	1183	group
O	1183	1184	,
O	1185	1188	the
B-outcome	1189	1199	proportion
I-outcome	1200	1202	of
I-outcome	1203	1211	patients
I-outcome	1212	1216	with
I-outcome	1217	1227	detectable
I-outcome	1228	1232	CTCs
O	1233	1236	was
O	1237	1244	similar
O	1245	1252	between
O	1253	1256	the
O	1257	1268	clopidogrel
O	1268	1269	/
O	1269	1276	aspirin
O	1277	1280	and
O	1281	1288	control
O	1289	1295	groups
O	1296	1298	at
O	1299	1307	baseline
O	1308	1309	(
O	1309	1310	P
O	1311	1312	=
O	1313	1314	.
O	1314	1316	21
O	1316	1317	)
O	1318	1321	and
O	1322	1323	4
O	1324	1329	weeks
O	1330	1331	(
O	1331	1332	P
O	1333	1334	=
O	1335	1336	.
O	1336	1338	75
O	1338	1339	)
O	1339	1340	,
O	1341	1348	showing
O	1349	1351	no
O	1352	1361	treatment
O	1362	1368	effect
O	1368	1369	.

B-outcome	1370	1378	Measured
I-outcome	1379	1389	endogenous
I-outcome	1390	1398	thrombin
I-outcome	1399	1408	potential
O	1409	1412	did
O	1413	1416	not
O	1417	1426	correlate
O	1427	1431	with
O	1432	1435	CTC
O	1436	1442	number
O	1442	1443	.

O	1444	1446	No
B-outcome	1447	1455	bleeding
I-outcome	1455	1456	-
I-outcome	1456	1463	related
I-outcome	1464	1471	serious
I-outcome	1472	1479	adverse
I-outcome	1480	1486	events
O	1487	1488	(
O	1488	1492	SAEs
O	1492	1493	)
O	1494	1502	occurred
O	1502	1503	.

O	1504	1507	The
O	1508	1516	baseline
O	1517	1520	CTC
O	1521	1528	numbers
O	1529	1533	were
O	1534	1539	lower
O	1540	1544	than
O	1545	1553	expected
O	1553	1554	,
O	1555	1565	decreasing
O	1566	1569	the
O	1570	1577	ability
O	1578	1580	to
O	1581	1587	detect
O	1588	1590	an
O	1591	1597	impact
O	1598	1600	of
O	1601	1609	platelet
O	1610	1620	inhibition
O	1621	1623	on
O	1624	1628	CTCs
O	1628	1629	.

O	1630	1641	Clopidogrel
O	1642	1645	and
O	1646	1653	aspirin
O	1654	1658	were
O	1659	1663	well
O	1664	1673	tolerated
O	1673	1674	.

O	1675	1681	Future
O	1682	1689	studies
O	1690	1700	evaluating
O	1701	1704	the
O	1705	1714	potential
O	1715	1726	therapeutic
O	1727	1731	role
O	1732	1734	of
O	1735	1747	antiplatelet
O	1748	1755	therapy
O	1756	1758	in
O	1759	1765	breast
O	1766	1772	cancer
O	1773	1779	remain
O	1780	1782	of
O	1783	1791	interest
O	1791	1792	,
O	1793	1796	and
O	1797	1801	they
O	1802	1805	may
O	1806	1808	be
O	1809	1817	informed
O	1818	1820	by
O	1821	1826	these
O	1827	1834	results
O	1834	1835	.
